Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) Narrows Q3 Loss Ahead of February 2027 PDUFA Decision
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating
Loading...